Claim Missing Document
Check
Articles

Found 2 Documents
Search

MANAGEMENT OF ADRENO CORTICAL CARCINOMA: CASE REPORT Duha, Diki Arma; Mirza, Hendy
Indonesian Journal of Urology Vol 29 No 1 (2022)
Publisher : Indonesian Urological Association

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32421/juri.v29i1.730

Abstract

Objective: Adreno cortical carcinoma (ACC) is a rare malignancy. Currently, surgical resection offers the best chance of cure with localized tumor. Multimodal therapy including systemic chemotherapy and radiation therapy are often required for locally advanced and metastatic disease aims to decrease these high recurrence rates. Case(s) presentation: A 42-year-old male patient was referred from internist due to mass in left adrenal. Solid mass with calcification on left adrenal gland within size 9 x 11.8 x 11.5 cm was found in MSCT. We performed complete surgical resection (adrenalectomy), and results from pathology anatomy was ACC functional T2N1M0 (stage 3). The patient was planned eight times chemotherapy with etoposide and carboplatin, but he decided to stop the treatment after six times due to no constitutional complaint. We found no residual mass on follow up six months after operation and patient demonstrated a good clinical outcome after one year. Discussion: We perform open adrenalectomy and after surgery mitotane plus etoposide, cisplatin, doxorubicin (EDP) administered as first-line therapy but we only did chemotherapy with etoposide and carboplatin because mitotane was not covered by patient insurance. We chose to not perform radiation therapy due to lesser benefit of adjuvant radiotherapy as evidenced by many studies in term of recurrence-free survival and overall survival. Conclusion: In our case, adreno cortical carcinoma treated with open adrenalectomy combined with 6 times chemotherapy used etoposide and carboplatin demonstrated a good clinical outcome after 1 year.
Comparative Analysis of En-Bloc and Conventional Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis Reynaldo, Reynaldo; Monoarfa, Richard Arie; Duha, Diki Arma
Jurnal Aisyah : Jurnal Ilmu Kesehatan Vol 9, No 1 (2024): March 2024
Publisher : Universitas Aisyah Pringsewu

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30604/jika.v9i1.2285

Abstract

In order to treat non-muscle invasive bladder cancer, this study will compare and contrast conventional transurethral resection of bladder tumors (TURBT) with En-bloc resection (ERBT). It will also assess the efficacy, safety, and recurrence rates of these two methods. We searched PubMed and Sience Direct for relevant articles published between 2013 and 2023. Articles from randomized controlled trials, retrospective analyses, and prospective studies comparing non-muscle invasive bladder cancer therapies employing en bloc versus conventional TURBT are included in this analysis. Measuring effect size was done using Mean Difference (MD) and Odd Ratio (OR) with 95% CI. There is statistical significance when the p-value is less than 0.05. Fourteen studies were eligible for inclusion. With fewer tumor recurrences (OR 0.66; 95% [CI]  0.52, 0.84; I2 = 6%; P = 0.0007), ERBT proved to be superior to TURBT. There was a decrease in the occurrence of perioperative complications and outcomes associated with ERBT, including bladder perforation and obturator nerve injury.  According to the fourteen articles that were included, patients receiving ERBT experienced much fewer complications, recurrences, hospital stays, and catheterization time than those receiving conventional TURBT.